Thank you for donating!

You can donate using the following services.

MNK Announcement Jan 2021

Posted: 20.01.21

We have received the following statement from Mallinckrodt Pharmaceuticals, stating their intention to discontinue clinical development of adrabetadex (VTS-270) for Niemann-Pick Type C1 disease (NPC), effective immediately. We understand that this will be very difficult news for many within our community; the NPUK team will be available if you would like to contact us: email or telephone 0191 415 06 93.

MNK Announcement Jan 2021 NPUK

A community webinar will take place on Friday 22nd January at 17.30.  The webinar will feature Dr. Steve Romano, Executive Vice President and Chief Scientific Officer at Mallinckrodt, and Dr. Susan VanMeter, Senior Clinical Director, who will address this latest news and take your questions. Please find details below:

Date: Friday, January 22

Time: 17.30- 18.30 GMT 12:30-1:30 p.m. EST

Join Zoom Meeting:

Passcode: 050409